Pharmacodynamic studies (PD) of didanosine (ddI) alone and in combination with azidothymidine (AZT) in human T-cells; A stochastic biochemical approach to antiretroviral nucleoside drug combination in inhibiting HIV-reverse transcriptase (RT)

In Vivo

Volumn 14, Issue 3, 2000, Pages 377-388

  Periclou, Antonia P ^a   Nandy, Partha ^a   Avramis, Vassilios I ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

AZT, ddI, 3TC, HIV RT, combination studies

Indexed keywords

ANTIVIRUS AGENT; DIDANOSINE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; THYMIDINE KINASE; ZIDOVUDINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INHIBITION; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; T LYMPHOCYTE; TREATMENT OUTCOME;

EID: 0033946835     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Richman DD, Fischl MA, Grieco MH et al: The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med 317: 192-197, 1987.
2. Fischl MA, Richman DD, Causey DM et al: Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex: JAMA 262: 2405-2410, 1989.
3. Kahn JO, Lagakos SW, Richman DD et al: A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 327: 581-587, 1992.
4. Furman PH, Fyfe JA, St Clair MH, et al: Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 83: 8333-8335, 1986.
5. Avramis VI, Markson W, Jackson RL and Gomperts E. Biochemical Pharmacology of Zidovudine (AZT) in Human T-Lymphoblasoid Cells (CEM). AIDS 3: 417-422, 1989.
6. Ahluwalia G, Cooney DA, Mitsuya H, et al: Initial studies on the cellular pharmacology of 2'3'-dideoxyinosine, an inhibitor of HIV infectivity. Biochem Pharmacol 36: 3797-3800, 1987.
7. Back DJ, Ormesher S, Tjia JF and Macleod R: Metabolism of 2'3'-ideoxyinosine (ddI) in human blood. Br J Clin Pharmacol 33: 319-322, 1992.
8. Shelton MJ, O'Donell AM and Morse GD: Didanosine. Ann Pharmacother 26: 660-669, 1992.
9. Nair V and Sells TB: Interpretation of the roles of adenylosuccinate lyase and of AMP deaminase in the anti-HIV activity of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine. Biochim Biophys Acta, 1119: 201-204, 1992.
10. Valentine FT, Seidlin M and Hochster H: Phase I study of 2',3'-dideoxyinosine: Experience with 19 patients at New York University Medical Center. Rev Inf Dis 12: S534-S539, 1990.
11. Valentine C and Foulis A: Alpha trial: pancreatitis on didanosine (ddI) risk factors and pathological features. The MRC/ANRS Coordinating Committee of the European/ Australian Alpha Trial. Int Conf AIDS 9: 477,1993.
12. St Clair MH, Martin JL, Tudor-Williams G, et al: Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253: 1557-1554, 1991.
13. Larder BA and Kemp SD: Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246; 1155-1158, 1989.
14. Mitsuya H, Yarchoan R, Kageyama S, et al: Targeted therapy of human immunodeficiency virus-related disease. FASEB 5: 2364-2381, 1991.
15. Fischl MA, Richman DD, Grieco MH, et al: The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 317: 185-191, 1987.
16. Yarchoan R, Mitsuya H, Myers CE and Broder S: Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleotides. N Engl J Med 321: 726-738, 1989.
17. Husson RN, Farley M, Woods L, et al: Zidovudine and didanosine combination therapy in children with human immunodefficiency virus infection. J Pediatrics 93: 316-322, 1994.
18. Avramis VI, Huang SH and Holcenberg JS: Drug synerglsm, antagonism and collateral sensitivity involving genetic changes. In Chou T-C and Rideout DC (eds), Synergism and antagonism in chemotherapy, Academic Press, Inc., San Diego, p. 585-619, 1991.
19. Collier AC, Coombs RW, Fischl MA, et al: Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann Intern Med 119: 786-793, 1993
20. Hart GJ, Orr DC, Penn CR et al: Effects of (-)-2'3'-deoxy-3'thiacytidine (3TC) 5'triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta and gamma. Antimicrob Agents Chemother, 36: 1688-1694, 1992.
21. Yarchoan R, Lietzau JA, Nguyen B-Y et al: A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection. J Inf Dis, 169: 9-17, 1994.
22. Gao WY, Shirasaka T, Johns DG et al: Differential phosphorylation of azidothymidine, deoxycytidine and deoxyinosine in resting and activated blood mononuclear cells. J Clin Invest 91: 2326-2333, 1993.
23. Avramis VI, Solorzano MM, Kwock R et al: Biochemical pharmacology of azidothymidine triphosphate (AZTTP) in PBMC cells from patients infected with HIV-1 who are receiving AZT and ddI in combination or AZT monotherapy. Proc. IX Intl. Conf. on AIDS, 1: 502, Abstr.#PO-B30-2202, Berlin, 1993.
24. Avramis VI, Kwock R, Solorzano MM et al: Evidence of in vitro development of drug resistance to azidothymidine (AZT) in T-lymphocytic leukemia cell lines (Jurkat E6-1 /AZT-100) and in pediatric patients with HIV-1 infection. J AIDS 6: 1287-1296, 1993.
25. Periclou AP and Avramis VI: Development of a population pharma cokinetic model (PPM) to describe didanosine (ddI) and azidothymidine (AZT) interaction after a combination treatment in pediatric patients with HIV-1 infection. Proc.4th European Conf. Clin. Aspects & Treat, of HIV-1 Infect., p.180, Abstr. #P 259, Milan Italy, March 1994.
26. Wientjes MG and Au JL-S: Lack of pharmacokinetic interaction between 2',3'-dideoxyinosine and 3'-deoxythymidine in rats. Antim Agents Chem 36: 665-668, 1992.
27. Gao WY, Agbaria R, Driscoll JS, et al: Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2',3'-dideoxynucleoside analogs in resting and activated human cells. J Biol Chem 269: 12633-12638, 1994.
28. Hoggard P. Veal G, Wild M, et al: Drug interactions with zidovudine phosphorylation in vitro. AIDS, 8(S4): S22, Abstr. #P13, 1994.
29. Periclou AP, Solorzano MM and Avramis VI: Comparative anaholism of Azidothymidine (AZT) and didanosine (ddI) in human T-cell lines sensitive and resistant to AZT and human PBMC cells. Proc Am Assoc Cancer Res 55: 333, Ahstr. # 1982,1994.
30. Richman DD, Kornhluth RS and Carson DA. Failure of dideoxynucleosides to inhibit human immunodeficiency virus replication in cultured human macrophages. J Exp Med 166: 1144-1149, 1997.
31. Perno C-F, Yarchoan R, Balzarini J, et al: Different pattern of activity of inhibitors of the human immunodeficiency virus in lymphocytes and monocyte/macrophages. Antiv Res 17: 289-304, 1992.
32. Ba-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides. J Exp Med 168: 1111-1125, 1988.
33. Periclou AP Solorzano MM and Avramis VI: Drug synergism by nucleoside analog drugs against HIV-RTbased on multiple inhibitor kinetics. Proc Am Assoc Cancer Res 36: 297, Abstr. #1769, 1995.
34. Kedar PS, Abbotts J, Kovacs T, et al: Mechanism of HIV reverse transcriptase: Enzyme-primer interaction as revealed through studies of a dNTP analogue, 3'-Azido-dTTP. Biochemistry 29: 3603-3611, 1990.
35. Boehringer-Mannheim Biochemical Cat. ''Reverse Transcriptase Assay, Non-radioactiven, p.504, 1995.
36. Hao Z, Cooney DA, Hartman NR, et al: Factors determining the activity of 2',3'-dideoxynucleosides in suppressing human immunodeficiency virus in vitro. Mol Pharmacol 34: 431-435, 1988.
37. Ueno T and Mitsuya H. Comparative enzymatic study of HIV-1 reverse transcriptase resistant to 2',3'-dideoxy nucleoside analogs using the single-nucleoside incorporation assay. Biochemistry 36: 1092-1099, 1997.
38. Jackson RC. The role of ribonucleotide reductase in regulation of deoxyribonucleoside triphosphate pool composition: Studies with a kinetic model. In Cory JC and Cory AH (eds), Inhibitors of ribonucleoside triphosphate reduetase activity, Pergamon Press, Inc., NewYork, P. 127-150, 1989.
39. Grindey GB and Cheng YC: Biochemical and kinetic approaches to inhibition of multiple pathways. Pharmac Ther 4: 307-327, 1979.
40. Periclou AP, Solorzano MM and Avramis VI: Comparative anabolism of azidothymidine (AZT) and didanosine (ddI) in human T-cell lines and PBMC cells sensitive and resistant to AZT. Proc. 4th European Conf. Clin. Aspects & Treat. of HIV-1 Infect., p.217, Abstr. #O 51, Milan Italy, March 1994.
41. Stretcher BN, Pesce AJ, Frame PT, et al: Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 38: 1541-1547, 1994.
42. Stretcher BN, Pesce AJ, Frame PT, et al: Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity. AIDS 8: 763-769, 1994.
43. Johnson MA, Ahluwalia G, Connelly MC, et al: Metabolic pathways for the activation of the antiretroviral agent 2',3'-dideoxyadenosine in human lymphoid cells. J Biol Chem 263: 15354-15357, 1988.
44. Dornsife RE, St Clair MH, Huang AT, et al: Anti-human immunodeficiency virus synergism by zidovudine (3'-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells. Antimicrob Agents Chemother 35: 322-328, 1991.
45. Cox SW, Albert J, Ljungdahl-Stahle E, et al: Effect of resistance on combination chemotherapy for human immunodeficiency virus infection. Advan Enz Regul 33: 27-36, 1993.
46. Larder BA, Purifoy DJ, Powell KL, et al: Site-specific mutagenesis of AIDS virus reverse transcriptase. Nature 327: 716-717, 1987.
47. Agarwal RP and Mian AM: Thymidine and zidovudine metabolism in chronically zidovudine-exposed cells in vitro. Biochem Pharmacol 42: 905-911, 1991.
48. Lori F, Malykh A, Cara A, et al: Hydroxyurea as an inhibitor of human immunodeficiency virus type 1 replication. Science 266: 801-805, 1994.
49. in vivo 14: 389-392 (2000)